肌因子在慢性肾脏病动脉粥样硬化过程中的作用及机制

袁 小越, 夏运 风*
重庆医科大学附属第一医院　肾脏内科　泌尿系统疾病代谢与免疫实验室

摘要


动脉粥样硬化是慢性肾脏病（chronic kidney disease，CKD）患者心脑血管病变的突出表现，由此引起的心脑血管事件是导致CKD患者死亡的主要原因。近期有研究揭示肌因子在CKD动脉粥样硬化的发生、发展中发挥了重要作用。此综述将深入探讨CKD中动脉粥样硬化的发病机制及肌因子在其中的调控作用，希望为CKD动脉粥样硬化的防治提供科学指导。

关键词


慢性肾脏病；动脉粥样硬化；肌因子

全文:

PDF


参考


[1]Jager K J, Kovesdy C, Langham R, et al. A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases[J]. Kidney International, 2019, 96(5): 1048-1050.

[2]Wang L, Xu X, Zhang M, et al. Prevalence of Chronic Kidney Disease in China[J]. JAMA Intern Med, 2023, 183(4): 298-310.

[3]Go A S, Chertow G M, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization[J]. N Engl J Med, 2004, 351(13): 1296-1305.

[4]Picciotto D, Macciò L, Verzola D, et al. Pathophysiology of Physical Exercise in Kidney Patients: Unveiling New Players - The Role of Myokines[J]. Kidney Blood Press Res, 2024, 49(1): 457-471.

[5]Libby P, Buring J E, Badimon L, et al. Atherosclerosis[J]. Nat Rev Dis Primers, 2019, 5(1): 56.

[6]Kanbay M, Yerlikaya A, Sag A A, et al. A journey from microenvironment to macroenvironment: the role of metaflammation and epigenetic changes in cardiorenal disease[J]. Clin Kidney J, 2019, 12(6): 861-870.

[7]Kim J Y, Park J T, Kim H W, et al. Inflammation Alters Relationship Between High‐Density Lipoprotein Cholesterol and Cardiovascular Risk in Patients With Chronic Kidney Disease: Results From KNOW‐CKD[J]. J Am Heart Assoc, 2021, 10(16): e021731.

[8]Lin A, Miano J M, Fisher E A, et al. Chronic inflammation and vascular cell plasticity in atherosclerosis[J]. Nat Cardiovasc Res, 2024, 3(12): 1408-1423.

[9]Zhu Y, Xian X, Wang Z, et al. Research Progress on the Relationship between Atherosclerosis and Inflammation[J]. Biomolecules, 2018, 8(3): 80.

[10]Kishi S, Nagasu H, Kidokoro K, et al. Oxidative stress and the role of redox signalling in chronic kidney disease[J]. Nat Rev Nephrol, 2024, 20(2): 101-119.

[11]Batty M, Bennett M R, Yu E. The Role of Oxidative Stress in Atherosclerosis[J]. Cells, 2022, 11(23): 3843.

[12]Liakopoulos V, Roumeliotis S, Gorny X, et al. Oxidative Stress in Hemodialysis Patients: A Review of the Literature[J]. Oxid Med Cell Longev, 2017, 2017: 3081856.

[13]Bermudez-Lopez M, Forne C, Amigo N, et al. An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients[J]. Expert Opin Ther Tar, 2019, 23(7): 619-630.

[14]Xiang Q, Tian F, Xu J, et al. New insight into dyslipidemia-induced cellular senescence in atherosclerosis[J]. Biol Rev, 2022, 97(5): 1844-1867.

[15]Baaten C C F M J, Vondenhoff S, Noels H. Endothelial Cell Dysfunction and Increased Cardiovascular Risk in Patients With Chronic Kidney Disease[J]. Circ Res, 2023, 132(8): 970-992.

[16]Wang Y, Wang M, Wang Y. Irisin: A Potentially Fresh Insight into the Molecular Mechanisms Underlying Vascular Aging[J]. Aging Dis, 2023, 15(6): 2491-2506.

[17]Cheng Z B, Huang L, Xiao X, et al. Irisin in atherosclerosis[J]. Clin Chim Acta, 2021, 522: 158-166.

[18]Hisamatsu T, Miura K, Arima H, et al. Relationship of serum irisin levels to prevalence and progression of coronary artery calcification: A prospective, population-based study[J]. Int J Cardiol, 2018, 267: 177-182.

[19]Hou Y C, Liao M T, Tsai K W, et al. Indoxyl sulfate induced frailty in patients with end-stage renal disease by disrupting the PGC-1α-FNDC5 axis[J]. Aging (Albany NY), 2023, 15(20): 11532-11545.

[20]Pan Y J, Zhou S J, Feng J, et al. Urotensin II Induces Mice Skeletal Muscle Atrophy Associated with Enhanced Autophagy and Inhibited Irisin Precursor (Fibronectin Type III Domain Containing 5) Expression in Chronic Renal Failure[J]. Kidney Blood Press Res, 2019, 44(4): 479-495.

[21]Batra G, Ghukasyan Lakic T, Lindbäck J, et al. Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome[J]. JAMA Cardiology, 2021, 6(12): 1440-1445.

[22]Ridker P M, Rane M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease[J]. Circulation Research, 2021, 128(11): 1728-1746.

[23]IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial[J]. The Lancet, 2021, 397(10289): 2060-2069.

[24]Damay V A, Setiawan S, Lesmana R, et al. Effects of Moderate Intensity Aerobic Exercise to FSTL-1 Regulation in Atherosclerosis: A Systematic Review[J]. Int J Angiol, 2022, 32(1): 1-10.

[25]Miyabe M, Ohashi K, Shibata R, et al. Muscle-derived follistatin-like 1 functions to reduce neointimal formation after vascular injury[J]. Cardiovasc Res, 2014, 103(1): 111-120.

[26]Endothelial cells exposed to atheroprotective flow secrete follistatin-like 1 protein which reduces transcytosis and inflammation[J]. Atherosclerosis, 2021, 333: 56-66.

[27]Zhang Y, Liu C, Liu J, et al. Implications of C1q/TNF-related protein superfamily in patients with coronary artery disease[J]. Sci Rep, 2020, 10(1): 1-11.

[28]Tan W H, Peng Z L, You T, et al. CTRP15 promotes macrophage cholesterol efflux and attenuates atherosclerosis by increasing the expression of ABCA1[J]. J Physiol Biochem, 2022, 78(3): 653-666.

[29]Ahmadi R, Fadaei R, Shokoohi Nahrkhalaji A, et al. The impacts of C1q/TNF-related protein-15 and adiponectin on Interleukin-6 and tumor necrosis factor-α in primary macrophages of patients with coronary artery diseases[J]. Cytokine, 2021, 142: 155470.

[30]Zhang J, Hu W, Lin P, et al. Decreased serum myonectin concentrations in diabetic nephropathy patients[J]. Clin Exp Med, 2020, 20(4): 601-607.

[31]Esposito P, Verzola D, Picciotto D, et al. Myostatin/Activin-A Signaling in the Vessel Wall and Vascular Calcification[J]. Cells, 2021, 10(8): 2070.

[32]Verzola D, Barisione C, Picciotto D, et al. Emerging role of myostatin and its inhibition in the setting of chronic kidney disease[J]. Kidney International, 2019, 95(3): 506-517.

[33]Baião V M, Cunha V A, Duarte M P, et al. Effects of Exercise on Inflammatory Markers in Individuals with Chronic Kidney Disease: A Systematic Review and Meta-Analysis[J]. Metabolites, 2023, 13(7): 795.

[34]Cosio P L, Crespo-Posadas M, Velarde-Sotres Á, et al. Effect of Chronic Resistance Training on Circulating Irisin: Systematic Review and Meta-Analysis of Randomized Controlled Trials[J]. Int J Environ Res Public Health, 2021, 18(5): 2476.

[35]Chow L S, Gerszten R E, Taylor J M, et al. Exerkines in health, resilience and disease[J]. Nat Rev Endocrinol, 2022, 18(5): 273-289.

[36]Otaka N, Shibata R, Ohashi K, et al. Myonectin Is an Exercise-Induced Myokine That Protects the Heart From Ischemia-Reperfusion Injury[J]. Circ Res, 2018, 123(12): 1326-1338.

[37]Wong L, McMahon L P. Crosstalk between bone and muscle in chronic kidney disease[J]. Front Endocrinol., 2023, 14: 1146868.


Refbacks

  • 当前没有refback。